Alessandro Antonelli, Alessandro Veccia, Sarah Malandra, Riccardo Rizzetto, Vincenzo De Marco, Alberto Baielli, Andrea Franceschini, Francesca Fumanelli, Francesca Montanaro, Iolanda Palumbo, Greta Pettenuzzo, Luca Roggero, Maria Angela Cerruto, Riccardo Bertolo, Michele Aloe, Francesco Artoni, Paolo Bianchi, Claudio Brancelli, Sonia Costantino, Peres Fokana Pongmoni, Piero Fracasso, Giulia Marafioti Patuzzo, Antonio Raiti, Endri Toska, and Vincenzo Vetro
Background and objective: The Hugo RAS and DaVinci Xi systems are used for performing robot-assisted radical prostatectomy (RARP). This study aims to compare these two platforms providing granular and comprehensive data on their intraoperative performance. Methods: The Comparison of Outcomes of Multiple Platforms for Assisted Robotic surgery—Prostate (COMPAR-P) trial is a prospective post-market study (clinicaltrials.org NCT05766163). Enrollment began in March 2023, allocating patients to DaVinci or Hugo RAS for RARP, without selection criteria, for up to 50 consecutive cases. Two experienced console surgeons performed the procedures, following the same technique. Evaluation focused on timing, learning curves, malfunctioning events, complications, and users’ satisfaction, using standard statistical methods, including the cumulative summation analysis (CUSUM) for the learning curve assessment. Key findings and limitations: Fifty patients each were enrolled for DaVinci (DV-RARP) and Hugo RAS (H-RARP) RARP. Baseline features were balanced. DV-RARP showed significantly shorter “setup” and “console” phase durations than H-RARP (37 vs 55 min and 97 vs 126 min, respectively, p